To Chemo or Not to Chemo? How Genomic Tests Provide a Definitive Answer
One of the most anxiety-inducing moments after breast cancer surgery is waiting to find out if you will need chemotherapy. The role of chemotherapy after surgery is to prevent recurrence or return of cancer in future. For decades, the decision was based on traditional factors: the size of the tumor, its grade, and whether it had traveled to the lymph nodes. If the features looked even slightly concerning, chemotherapy was given as a standard safety net.
Today, precision medicine allows us to look much deeper. We no longer just look at the tumor under a microscope; we look inside its "brain"—its genetic signature. The benefit of chemotherapy in patient is now being questioned, and can the patient with a particular suitable profile (Hormone Receptor positive and early stage) be spared from it safely.
Through advanced genomic testing, we can now predict with incredible accuracy whether your specific cancer is highly likely to return, and more importantly, whether chemotherapy will actually help you.
What is a Genomic Test? (And What It Is Not)
It is very common to confuse genetic testing with genomic testing, but they serve completely different purposes:
>Genetic Testing (The Family History): This tests your blood to see if you inherited a faulty gene (like BRCA1 or BRCA2) that increases your lifetime risk of developing cancer.
>Genomic Testing (The Tumor's Behavior): This tests the actual tumor tissue that was removed during your surgery or biopsy. It analyzes the specific set of genes driving that tumor's growth to see how aggressively it behaves.
Think of a genomic test as a weather forecast for your recovery. It tells us if there is a storm brewing (high risk of recurrence) or clear skies ahead (low risk), allowing us to tailor your treatment with absolute precision.
The Two Tests We Use Routinely: Oncotype DX and CanAssist
In our practice, we routinely utilize two world-class genomic tests for patients who have Hormone Receptor-Positive (ER/PR positive), HER2-negative early-stage breast cancer. Both tests give us a personalized "Recurrence Score," but they are tailored to different clinical scenarios and financial roadmaps.
1. Oncotype DX (The Global Gold Standard)
This is a widely recognized international test that analyzes a panel of 21 specific genes within the tumor.
How it works: It provides a score from 0 to 100. A low score means the cancer has a very low risk of returning, and chemotherapy offers virtually 0% added benefit. A high score indicates that chemotherapy is essential to protect your future health.
>Consideration: The tissue sample is sent to a central laboratory in the USA, which means it carries a premium international cost and takes about 2 to 3 weeks for results.
2. CanAssist Breast (The Made-for-India Innovation)
For many patients navigating treatment in India, we utilize CanAssist Breast—an incredible, clinically validated genomic test developed specifically keeping affordable care in mind.
How it works: It analyzes a distinct combination of protein biomarkers using machine learning to classify patients into "Low Risk" or "High Risk" categories.
>Consideration: Because it is processed right here in India, it provides a highly accurate, robust roadmap at a fraction of the cost of international tests, making precision medicine accessible to many more families.
The Impact: Sparing You from Unnecessary Over-Treatment
The data from these tests is revolutionary. Globally, these genomic insights have allowed up to 70% to 80% of patients with early-stage, hormone-positive breast cancer to safely skip chemotherapy altogether.
Instead of enduring the physical, emotional, and financial toll of chemo, low-risk patients can confidently proceed directly to standard, much gentler hormone therapies (pills) knowing they are not compromising their cure.
Conversely, if the test shows a high-risk score, it gives you and your family the absolute mental certainty that chemotherapy is a necessary, life-saving step in your roadmap. It eliminates the guesswork.
Your Tailored Treatment Roadmap
Genomic testing is the ultimate tool for avoiding both under-treatment and unnecessary over-treatment. However, these tests are highly specific and are not required for every single type of breast cancer (for instance, it is not applicable for Triple-Negative or HER2-positive cancers that require chemotherapy regardless of stage).
As your surgical care team, once we have your complete post-surgery pathology report, we will discuss whether an Oncotype DX or CanAssist test is the right next step for your specific biology and financial comfort.
Precision care means treating your cancer aggressively, but protecting your body fiercely. Let's design the exact roadmap your body needs.